Other risky bets include a drug that aims to prevent heart attacks by combating artery inflammation, and a partnership with Anacor, a San Francisco company that makes drugs based on a new type of chemistry involving the element boron.
One drug Glaxo is testing in early human trials is licensed from biotech company Anacor Pharmaceuticals and uses a new type of chemistry based on the element boron.